Postoperative Gastrointestinal Dysfunction After Neuromuscular Blockade Reversal With Sugammadex Versus Cholinesterase Inhibitors in Patients Undergoing Gastrointestinal Surgery: A Systematic Review and Meta-Analysis
Background Postoperative gastrointestinal dysfunction (POGD) commonly occurs following gastrointestinal (GI) surgery and is associated with specific anesthetic agents. Cholinesterase inhibitors employed for reversing neuromuscular blockade have been implicated in development of POGD. Sugammadex, a n...
Gespeichert in:
| Veröffentlicht in: | The American Surgeon 2024-06, Vol.90 (6), p.1618-1629 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1629 |
|---|---|
| container_issue | 6 |
| container_start_page | 1618 |
| container_title | The American Surgeon |
| container_volume | 90 |
| creator | Sharma, Sahil McKechnie, Tyler Talwar, Gaurav Patel, Janhavi Heimann, Luke Doumouras, Aristithes Hong, Dennis Eskicioglu, Cagla |
| description | Background
Postoperative gastrointestinal dysfunction (POGD) commonly occurs following gastrointestinal (GI) surgery and is associated with specific anesthetic agents. Cholinesterase inhibitors employed for reversing neuromuscular blockade have been implicated in development of POGD. Sugammadex, a novel reversal agent, is linked with reduced POGD. However, there is a lack of comprehensive comparative review between these agents regarding their impact on POGD following GI surgery. This study aims to systematically review the effects of sugammadex on POGD compared to cholinesterase inhibitors following GI surgery.
Methods
MEDLINE, EMBASE, and CENTRAL were searched as of July 2022 to identify articles comparing sugammadex with cholinesterase inhibitors in patients undergoing gastrointestinal surgery, specifically in relation to POGD. Secondary endpoints included length of hospital stay, readmission rates, pulmonary complications, and postoperative morbidity.
Results
From 198 citations, 2 randomized controlled trials (RCTs) and 3 retrospective cohorts with 717 patients receiving sugammadex and 812 patients receiving cholinesterase inhibitors were included. Significantly lower rates of prolonged postoperative ileus (OR .44, 95% CI .25-.77, P < .05, I2 = 56%, low certainty evidence) was observed with sugammadex. No significant difference in any other outcome was observed. Narrative review of readmission data demonstrated no significant difference.
Conclusion
The use of sugammadex following gastrointestinal surgery is associated with significantly lower rates of prolonged postoperative ileus compared to cholinesterase inhibitors. However, these do not translate into a significant reduction in length of stay, morbidity, or postoperative nausea and vomiting. Results are limited by the numer of studies included and missing data, more robust RCTs are needed before recommendations can be made. |
| doi_str_mv | 10.1177/00031348241227200 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2913449053</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_00031348241227200</sage_id><sourcerecordid>2913449053</sourcerecordid><originalsourceid>FETCH-LOGICAL-c383t-1cc8e7b50752d76d5b66c0dd57c817fc40328f4eff8c0f507f7ff8169ee643cf3</originalsourceid><addsrcrecordid>eNp9kc9u1DAQxi0EokvhAbggH7mk2HH-clsWKJUKVCyFY-R1xlmXxN567LZ5Ux4Hr7ZwqcTJ9vj3fTOaj5CXnJ1wXtdvGGOCi6LJC57ndc7YI7LgZVlmbZOLx2Sx_8_2wBF5hniVnkVV8qfkSDS8bauqXZDfFw6D24GXwdwAPZUYvDM2AAZj5Ujfz6ijVcE4S5c6gKdfIHo3RVRxlJ6-G536JXug3-AGPCbFTxO2dB0HOU2pfkd_pHJEutq60dhkm1oh0DO7NRsTnEdqLL1I3cEGpJe2Bz-kAYaHo6yjH8DPb-mSrufkMyWR2vc1cEul7elnCDJbJnRGg8_JEy1HhBf35zG5_Pjh--pTdv719Gy1PM-UaETIuFIN1JuS1WXe11VfbqpKsb4va9XwWquCibzRBWjdKKYTput05VULUBVCaXFMXh98d95dxzRrNxlUMI7SgovY5W0KoGhZKRLKD6jyDtGD7nbeTNLPHWfdPtDuQaBJ8-rePm4m6P8p_iaYgJMDgHKA7spFnxaA_3H8A3OPr48</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2913449053</pqid></control><display><type>article</type><title>Postoperative Gastrointestinal Dysfunction After Neuromuscular Blockade Reversal With Sugammadex Versus Cholinesterase Inhibitors in Patients Undergoing Gastrointestinal Surgery: A Systematic Review and Meta-Analysis</title><source>MEDLINE</source><source>SAGE Journals Online</source><creator>Sharma, Sahil ; McKechnie, Tyler ; Talwar, Gaurav ; Patel, Janhavi ; Heimann, Luke ; Doumouras, Aristithes ; Hong, Dennis ; Eskicioglu, Cagla</creator><creatorcontrib>Sharma, Sahil ; McKechnie, Tyler ; Talwar, Gaurav ; Patel, Janhavi ; Heimann, Luke ; Doumouras, Aristithes ; Hong, Dennis ; Eskicioglu, Cagla</creatorcontrib><description>Background
Postoperative gastrointestinal dysfunction (POGD) commonly occurs following gastrointestinal (GI) surgery and is associated with specific anesthetic agents. Cholinesterase inhibitors employed for reversing neuromuscular blockade have been implicated in development of POGD. Sugammadex, a novel reversal agent, is linked with reduced POGD. However, there is a lack of comprehensive comparative review between these agents regarding their impact on POGD following GI surgery. This study aims to systematically review the effects of sugammadex on POGD compared to cholinesterase inhibitors following GI surgery.
Methods
MEDLINE, EMBASE, and CENTRAL were searched as of July 2022 to identify articles comparing sugammadex with cholinesterase inhibitors in patients undergoing gastrointestinal surgery, specifically in relation to POGD. Secondary endpoints included length of hospital stay, readmission rates, pulmonary complications, and postoperative morbidity.
Results
From 198 citations, 2 randomized controlled trials (RCTs) and 3 retrospective cohorts with 717 patients receiving sugammadex and 812 patients receiving cholinesterase inhibitors were included. Significantly lower rates of prolonged postoperative ileus (OR .44, 95% CI .25-.77, P < .05, I2 = 56%, low certainty evidence) was observed with sugammadex. No significant difference in any other outcome was observed. Narrative review of readmission data demonstrated no significant difference.
Conclusion
The use of sugammadex following gastrointestinal surgery is associated with significantly lower rates of prolonged postoperative ileus compared to cholinesterase inhibitors. However, these do not translate into a significant reduction in length of stay, morbidity, or postoperative nausea and vomiting. Results are limited by the numer of studies included and missing data, more robust RCTs are needed before recommendations can be made.</description><identifier>ISSN: 0003-1348</identifier><identifier>EISSN: 1555-9823</identifier><identifier>DOI: 10.1177/00031348241227200</identifier><identifier>PMID: 38199669</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Cholinesterase Inhibitors - adverse effects ; Cholinesterase Inhibitors - therapeutic use ; Digestive System Surgical Procedures - adverse effects ; Gastrointestinal Diseases ; Humans ; Length of Stay ; Neuromuscular Blockade - adverse effects ; Neuromuscular Blockade - methods ; Postoperative Complications ; Sugammadex - administration & dosage ; Sugammadex - therapeutic use</subject><ispartof>The American Surgeon, 2024-06, Vol.90 (6), p.1618-1629</ispartof><rights>The Author(s) 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c383t-1cc8e7b50752d76d5b66c0dd57c817fc40328f4eff8c0f507f7ff8169ee643cf3</citedby><cites>FETCH-LOGICAL-c383t-1cc8e7b50752d76d5b66c0dd57c817fc40328f4eff8c0f507f7ff8169ee643cf3</cites><orcidid>0000-0001-8268-014X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/00031348241227200$$EPDF$$P50$$Gsage$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/00031348241227200$$EHTML$$P50$$Gsage$$Hfree_for_read</linktohtml><link.rule.ids>313,314,776,780,788,21799,27901,27903,27904,43600,43601</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38199669$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sharma, Sahil</creatorcontrib><creatorcontrib>McKechnie, Tyler</creatorcontrib><creatorcontrib>Talwar, Gaurav</creatorcontrib><creatorcontrib>Patel, Janhavi</creatorcontrib><creatorcontrib>Heimann, Luke</creatorcontrib><creatorcontrib>Doumouras, Aristithes</creatorcontrib><creatorcontrib>Hong, Dennis</creatorcontrib><creatorcontrib>Eskicioglu, Cagla</creatorcontrib><title>Postoperative Gastrointestinal Dysfunction After Neuromuscular Blockade Reversal With Sugammadex Versus Cholinesterase Inhibitors in Patients Undergoing Gastrointestinal Surgery: A Systematic Review and Meta-Analysis</title><title>The American Surgeon</title><addtitle>Am Surg</addtitle><description>Background
Postoperative gastrointestinal dysfunction (POGD) commonly occurs following gastrointestinal (GI) surgery and is associated with specific anesthetic agents. Cholinesterase inhibitors employed for reversing neuromuscular blockade have been implicated in development of POGD. Sugammadex, a novel reversal agent, is linked with reduced POGD. However, there is a lack of comprehensive comparative review between these agents regarding their impact on POGD following GI surgery. This study aims to systematically review the effects of sugammadex on POGD compared to cholinesterase inhibitors following GI surgery.
Methods
MEDLINE, EMBASE, and CENTRAL were searched as of July 2022 to identify articles comparing sugammadex with cholinesterase inhibitors in patients undergoing gastrointestinal surgery, specifically in relation to POGD. Secondary endpoints included length of hospital stay, readmission rates, pulmonary complications, and postoperative morbidity.
Results
From 198 citations, 2 randomized controlled trials (RCTs) and 3 retrospective cohorts with 717 patients receiving sugammadex and 812 patients receiving cholinesterase inhibitors were included. Significantly lower rates of prolonged postoperative ileus (OR .44, 95% CI .25-.77, P < .05, I2 = 56%, low certainty evidence) was observed with sugammadex. No significant difference in any other outcome was observed. Narrative review of readmission data demonstrated no significant difference.
Conclusion
The use of sugammadex following gastrointestinal surgery is associated with significantly lower rates of prolonged postoperative ileus compared to cholinesterase inhibitors. However, these do not translate into a significant reduction in length of stay, morbidity, or postoperative nausea and vomiting. Results are limited by the numer of studies included and missing data, more robust RCTs are needed before recommendations can be made.</description><subject>Cholinesterase Inhibitors - adverse effects</subject><subject>Cholinesterase Inhibitors - therapeutic use</subject><subject>Digestive System Surgical Procedures - adverse effects</subject><subject>Gastrointestinal Diseases</subject><subject>Humans</subject><subject>Length of Stay</subject><subject>Neuromuscular Blockade - adverse effects</subject><subject>Neuromuscular Blockade - methods</subject><subject>Postoperative Complications</subject><subject>Sugammadex - administration & dosage</subject><subject>Sugammadex - therapeutic use</subject><issn>0003-1348</issn><issn>1555-9823</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>EIF</sourceid><recordid>eNp9kc9u1DAQxi0EokvhAbggH7mk2HH-clsWKJUKVCyFY-R1xlmXxN567LZ5Ux4Hr7ZwqcTJ9vj3fTOaj5CXnJ1wXtdvGGOCi6LJC57ndc7YI7LgZVlmbZOLx2Sx_8_2wBF5hniVnkVV8qfkSDS8bauqXZDfFw6D24GXwdwAPZUYvDM2AAZj5Ujfz6ijVcE4S5c6gKdfIHo3RVRxlJ6-G536JXug3-AGPCbFTxO2dB0HOU2pfkd_pHJEutq60dhkm1oh0DO7NRsTnEdqLL1I3cEGpJe2Bz-kAYaHo6yjH8DPb-mSrufkMyWR2vc1cEul7elnCDJbJnRGg8_JEy1HhBf35zG5_Pjh--pTdv719Gy1PM-UaETIuFIN1JuS1WXe11VfbqpKsb4va9XwWquCibzRBWjdKKYTput05VULUBVCaXFMXh98d95dxzRrNxlUMI7SgovY5W0KoGhZKRLKD6jyDtGD7nbeTNLPHWfdPtDuQaBJ8-rePm4m6P8p_iaYgJMDgHKA7spFnxaA_3H8A3OPr48</recordid><startdate>202406</startdate><enddate>202406</enddate><creator>Sharma, Sahil</creator><creator>McKechnie, Tyler</creator><creator>Talwar, Gaurav</creator><creator>Patel, Janhavi</creator><creator>Heimann, Luke</creator><creator>Doumouras, Aristithes</creator><creator>Hong, Dennis</creator><creator>Eskicioglu, Cagla</creator><general>SAGE Publications</general><scope>AFRWT</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8268-014X</orcidid></search><sort><creationdate>202406</creationdate><title>Postoperative Gastrointestinal Dysfunction After Neuromuscular Blockade Reversal With Sugammadex Versus Cholinesterase Inhibitors in Patients Undergoing Gastrointestinal Surgery: A Systematic Review and Meta-Analysis</title><author>Sharma, Sahil ; McKechnie, Tyler ; Talwar, Gaurav ; Patel, Janhavi ; Heimann, Luke ; Doumouras, Aristithes ; Hong, Dennis ; Eskicioglu, Cagla</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c383t-1cc8e7b50752d76d5b66c0dd57c817fc40328f4eff8c0f507f7ff8169ee643cf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Cholinesterase Inhibitors - adverse effects</topic><topic>Cholinesterase Inhibitors - therapeutic use</topic><topic>Digestive System Surgical Procedures - adverse effects</topic><topic>Gastrointestinal Diseases</topic><topic>Humans</topic><topic>Length of Stay</topic><topic>Neuromuscular Blockade - adverse effects</topic><topic>Neuromuscular Blockade - methods</topic><topic>Postoperative Complications</topic><topic>Sugammadex - administration & dosage</topic><topic>Sugammadex - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sharma, Sahil</creatorcontrib><creatorcontrib>McKechnie, Tyler</creatorcontrib><creatorcontrib>Talwar, Gaurav</creatorcontrib><creatorcontrib>Patel, Janhavi</creatorcontrib><creatorcontrib>Heimann, Luke</creatorcontrib><creatorcontrib>Doumouras, Aristithes</creatorcontrib><creatorcontrib>Hong, Dennis</creatorcontrib><creatorcontrib>Eskicioglu, Cagla</creatorcontrib><collection>SAGE Journals Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The American Surgeon</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sharma, Sahil</au><au>McKechnie, Tyler</au><au>Talwar, Gaurav</au><au>Patel, Janhavi</au><au>Heimann, Luke</au><au>Doumouras, Aristithes</au><au>Hong, Dennis</au><au>Eskicioglu, Cagla</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Postoperative Gastrointestinal Dysfunction After Neuromuscular Blockade Reversal With Sugammadex Versus Cholinesterase Inhibitors in Patients Undergoing Gastrointestinal Surgery: A Systematic Review and Meta-Analysis</atitle><jtitle>The American Surgeon</jtitle><addtitle>Am Surg</addtitle><date>2024-06</date><risdate>2024</risdate><volume>90</volume><issue>6</issue><spage>1618</spage><epage>1629</epage><pages>1618-1629</pages><issn>0003-1348</issn><eissn>1555-9823</eissn><abstract>Background
Postoperative gastrointestinal dysfunction (POGD) commonly occurs following gastrointestinal (GI) surgery and is associated with specific anesthetic agents. Cholinesterase inhibitors employed for reversing neuromuscular blockade have been implicated in development of POGD. Sugammadex, a novel reversal agent, is linked with reduced POGD. However, there is a lack of comprehensive comparative review between these agents regarding their impact on POGD following GI surgery. This study aims to systematically review the effects of sugammadex on POGD compared to cholinesterase inhibitors following GI surgery.
Methods
MEDLINE, EMBASE, and CENTRAL were searched as of July 2022 to identify articles comparing sugammadex with cholinesterase inhibitors in patients undergoing gastrointestinal surgery, specifically in relation to POGD. Secondary endpoints included length of hospital stay, readmission rates, pulmonary complications, and postoperative morbidity.
Results
From 198 citations, 2 randomized controlled trials (RCTs) and 3 retrospective cohorts with 717 patients receiving sugammadex and 812 patients receiving cholinesterase inhibitors were included. Significantly lower rates of prolonged postoperative ileus (OR .44, 95% CI .25-.77, P < .05, I2 = 56%, low certainty evidence) was observed with sugammadex. No significant difference in any other outcome was observed. Narrative review of readmission data demonstrated no significant difference.
Conclusion
The use of sugammadex following gastrointestinal surgery is associated with significantly lower rates of prolonged postoperative ileus compared to cholinesterase inhibitors. However, these do not translate into a significant reduction in length of stay, morbidity, or postoperative nausea and vomiting. Results are limited by the numer of studies included and missing data, more robust RCTs are needed before recommendations can be made.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>38199669</pmid><doi>10.1177/00031348241227200</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0001-8268-014X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-1348 |
| ispartof | The American Surgeon, 2024-06, Vol.90 (6), p.1618-1629 |
| issn | 0003-1348 1555-9823 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2913449053 |
| source | MEDLINE; SAGE Journals Online |
| subjects | Cholinesterase Inhibitors - adverse effects Cholinesterase Inhibitors - therapeutic use Digestive System Surgical Procedures - adverse effects Gastrointestinal Diseases Humans Length of Stay Neuromuscular Blockade - adverse effects Neuromuscular Blockade - methods Postoperative Complications Sugammadex - administration & dosage Sugammadex - therapeutic use |
| title | Postoperative Gastrointestinal Dysfunction After Neuromuscular Blockade Reversal With Sugammadex Versus Cholinesterase Inhibitors in Patients Undergoing Gastrointestinal Surgery: A Systematic Review and Meta-Analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T19%3A37%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Postoperative%20Gastrointestinal%20Dysfunction%20After%20Neuromuscular%20Blockade%20Reversal%20With%20Sugammadex%20Versus%20Cholinesterase%20Inhibitors%20in%20Patients%20Undergoing%20Gastrointestinal%20Surgery:%20A%20Systematic%20Review%20and%20Meta-Analysis&rft.jtitle=The%20American%20Surgeon&rft.au=Sharma,%20Sahil&rft.date=2024-06&rft.volume=90&rft.issue=6&rft.spage=1618&rft.epage=1629&rft.pages=1618-1629&rft.issn=0003-1348&rft.eissn=1555-9823&rft_id=info:doi/10.1177/00031348241227200&rft_dat=%3Cproquest_cross%3E2913449053%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2913449053&rft_id=info:pmid/38199669&rft_sage_id=10.1177_00031348241227200&rfr_iscdi=true |